83 related articles for article (PubMed ID: 2114596)
1. Gamma-interferon in myelodysplastic syndromes: a pilot study.
Schwarzinger I; Stain C; Bettelheim P; Hinterberger W; Lechner K
Oncology; 1990; 47(4):322-6. PubMed ID: 2114596
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide for the treatment of patients with myelodysplastic syndromes.
Strupp C; Germing U; Aivado M; Misgeld E; Haas R; Gattermann N
Leukemia; 2002 Jan; 16(1):1-6. PubMed ID: 11840256
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human gamma interferon administered by continuous intravenous infusion in acute myelogenous leukemia and myelodysplastic syndromes.
Stone RM; Spriggs DR; Arthur KA; Mayer RJ; Griffin J; Kufe DW
Am J Clin Oncol; 1993 Apr; 16(2):159-63. PubMed ID: 8452111
[TBL] [Abstract][Full Text] [Related]
4. A trial of recombinant alpha 2 interferon in the myelodysplastic syndromes: I. Clinical results.
Elias L; Hoffman R; Boswell S; Tensen L; Bonnem EM
Leukemia; 1987 Feb; 1(2):105-10. PubMed ID: 3478534
[TBL] [Abstract][Full Text] [Related]
5. Treatment of advanced myelodysplastic syndromes with recombinant interferon-alpha 2b.
Aul C; Gattermann N; Schneider W
Eur J Haematol; 1991 Jan; 46(1):11-6. PubMed ID: 1988303
[TBL] [Abstract][Full Text] [Related]
6. [Clinical investigation of interferons in the preleukemic state (CML and MDS)].
Koyama S
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-2):1191-7. PubMed ID: 3132893
[TBL] [Abstract][Full Text] [Related]
7. [Retrospective analysis of hemotherapy support in 226 cases of myelodysplastic syndromes].
Rubio-Félix D; Franco E; Giraldo P; Gimeno J; Cuesta I; Giralt M
Sangre (Barc); 1994 Apr; 39(2):117-20. PubMed ID: 8059289
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of recombinant human interferon alpha in myelodysplastic syndromes.
Nand S; Ellis T; Messmore H; Fisher SG; Gaynor E; Fisher RI
Leukemia; 1992 Mar; 6(3):220-3. PubMed ID: 1564960
[TBL] [Abstract][Full Text] [Related]
9. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study.
Deeg HJ; Gotlib J; Beckham C; Dugan K; Holmberg L; Schubert M; Appelbaum F; Greenberg P
Leukemia; 2002 Feb; 16(2):162-4. PubMed ID: 11840280
[TBL] [Abstract][Full Text] [Related]
10. Recombinant gamma-interferon as first line therapy for high risk myelodysplastic syndromes. Italian MDS Study Group.
Maiolo AT; Cortelezzi A; Calori R; Polli EE
Leukemia; 1990 Jul; 4(7):480-5. PubMed ID: 2115613
[TBL] [Abstract][Full Text] [Related]
11. Amifostine in the treatment of low-risk myelodysplastic syndromes.
Grossi A; Fabbri A; Santini V; Leoni F; Nozzoli C; Longo G; Pagliai G; Ciolli S; Rossi Ferrini P
Haematologica; 2000 Apr; 85(4):367-71. PubMed ID: 10756361
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine-arabinoside in the treatment of patients with myelodysplastic syndromes. A phase II study.
Höffken K; Overkamp F; Stirbu J; Grothey A; Flasshove M; Hoelzer D; Ganser A
Onkologie; 1990 Feb; 13(1):33-7. PubMed ID: 2186322
[TBL] [Abstract][Full Text] [Related]
13. [Clinical study of rhG-CSF (KRN8601) in patients with myelodysplastic syndrome].
Toyama K; Ohyashiki J; Takaku F; Kobayashi Y; Miyazono K; Miura Y; Sakamoto S; Mizoguchi H; Hoshino S; Urabe A
Rinsho Ketsueki; 1990 Jul; 31(7):937-45. PubMed ID: 1699007
[TBL] [Abstract][Full Text] [Related]
14. [A phase III trial of subcutaneous administration of rhG-CSF in the myelodysplastic syndromes].
Yoshida Y; Okuma M; Suzuki T; Takahashi T; Nakagawa M; Kashima K; Abe T; Sonoda Y; Fujii H; Haruyama H
Rinsho Ketsueki; 1994 Nov; 35(11):1289-96. PubMed ID: 7529842
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon.
Grem JL; McAtee N; Murphy RF; Balis FM; Cullen E; Chen AP; Hamilton JM; Steinberg SM; Quinn M; Sorensen JM; Arbuck SG; Lawrence D; Pang J; Allegra CJ
Clin Cancer Res; 1997 Jul; 3(7):1125-34. PubMed ID: 9815792
[TBL] [Abstract][Full Text] [Related]
16. Autologous bone marrow transplantation with marrow purged by mafosfamide in seven patients with myelodysplastic syndromes in transformation (AML-MDS): a pilot study.
Laporte JP; Isnard F; Lesage S; Fenaux P; Douay L; Lopez M; Stachowiak J; Najman A; Gorin NC
Leukemia; 1993 Dec; 7(12):2030-3. PubMed ID: 8255103
[TBL] [Abstract][Full Text] [Related]
17. [Long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome: follow-up of 60 cases].
Guan M; Chen SC; Ge CW
Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):919-22. PubMed ID: 19671296
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human erythropoietin in the treatment of myelodysplastic syndromes. An interim report.
Aloe Spiriti MA; Petti MC; Latagliata R; Avvisati G; De Gregoris C; Proia S; Fazi P; Jaalouk G; Mancini M; Spadea A
Haematologica; 1993; 78(2):123-6. PubMed ID: 8349188
[TBL] [Abstract][Full Text] [Related]
19. [Secondary hemochromatosis in polytransfused patients with myelodysplastic syndromes].
Jaeger M; Aul C; Söhngen D; Germing U; Schneider W
Beitr Infusionsther; 1992; 30():464-8. PubMed ID: 1284762
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic effectiveness of vitamin D3 in patients with myelodysplastic syndromes, leukemias and myeloproliferative disorders].
Takahashi T; Ichiba S; Okuno Y; Sugiyama H; Sakai Y; Imura H; Iho S; Hoshino T; Suzuki A; Okada T
Rinsho Ketsueki; 1989 Jan; 30(1):1-10. PubMed ID: 2716194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
